Suven Life Sciences to showcase narcolepsy program Samelisant at SLEEP 2026
Samelisant will be the centerpiece of Suven’s scientific presence
Samelisant will be the centerpiece of Suven’s scientific presence
Global Phase-3 study initiation expected in the second half of 2024
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Subscribe To Our Newsletter & Stay Updated